Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

31.23 +0.72 (+2.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Top 5 Health Care Stocks That May Surge
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Dow Gains 150 Points After Fed Minutes
U.S. stocks traded higher toward the end of trading, following the release of minutes from the FOMC meeting. 
Via Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 63 companies set new 52-week lows. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Vera Therapeutics
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 35 companies reached new 52-week lows. 
Via Benzinga
Nasdaq Rises Over 100 Points; Crude Oil Drops Sharply
U.S. stocks extended gains midway through trading, with the Dow Jones gaining around 250 points on Wednesday ahead of the release of minutes from the Fed's meeting. 
Via Benzinga
These 2 Nasdaq Biotechs Are Making Big Moves Wednesday
The binary nature of biotech investing is making itself obvious from recent study results. 
Via The Motley Fool
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped
The "devil is in the details" when it comes to comparing data across studies. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
 
Via Benzinga
US Stocks Open Higher Ahead Of Fed Minutes; Dow Rises 100 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Wednesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Oblong Shares Are Trading Higher By 59%; Here Are 20 Stocks Moving Premarket
Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares rose 63.2% to $0.4201 in pre-market trading after dropping 8% on Tuesday. Elys Game Technology and Cloakbook were recently granted a license to... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! 
Via InvestorPlace
Vera Therapeutics Shares Plunge After Mixed Data From Rare Kidney Disease Study
 
Via Benzinga
Vera Therapeutics, Phathom Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Tesla, Amazon, Apple, Aurinia Pharma, Vera Therapeutics: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed in the red on Tuesday, the first trading day of 2023, as concerns over rising rates and inflation still seem to drive investor sentiments. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Present at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week
From Vera Therapeutics
Via GlobeNewswire
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results. 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Vera Therapeutics: Here's What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Vera Therapeutics (NASDAQ:VERA) and raise its price target from $35.00 to $36.00. Shares of Vera Therapeutics are trading down 1.88% over... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.